Inhibition of MARCKS has been shown to impair cell proliferation, invasion, migration, and mammosphere formation, and therefore, positioning it as a potential therapeutic target for 28% of MARCKS-positive inflammatory breast cancer patients (Manai et al., 2022). This evidence concerns the gene MARCKS and inflammatory breast carcinoma.